Compassionate Use (Nordic countries): how it works and where it is recognized
A cross-border regulatory framework for supplying an unregistered or off-label medicine to a specific patient, on the order of a treating physician, under a defined permit issued by the destination-country medicines regulator.
Last reviewed 2026-05-16 by Reserve Meds clinical and regulatory team.
What Compassionate Use (Nordic) is
Origin and authorising body. Nordic countries (Denmark, Sweden, Norway, Finland) under EMA Article 83 of Regulation (EC) No 726/2004, implemented through national pharmacy agencies. The authorising body for each individual case is the Lakemedelsverket (Sweden), Laegemiddelstyrelsen (Denmark), Statens legemiddelverk (Norway), Fimea (Finland), acting under that jurisdiction's pharmacy or medicines legislation.
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
Legal basis. Each Nordic country implements EMA Article 83 compassionate-use guidance through its national pharmacy agency. Sweden's Lakemedelsverket authorises licensgranted permits for unregistered medicines under Section 5 of the Medicinal Products Act. Denmark's Laegemiddelstyrelsen administers udleveringstilladelse permits. Norway's Statens legemiddelverk operates registreringsfritak permits under the Medicines Act. Finland's Fimea administers erityislupa permits under the Medicines Act.
Compassionate Use across the Nordic countries operates through a shared regulatory philosophy with country-specific implementations. The Nordic framework is among the most operationally efficient in Europe: applications are typically processed within 5 to 15 business days, the dispensing infrastructure is well established, and physicians and pharmacies are accustomed to the workflow. The Nordic framework is widely used for late-Phase 3 oncology agents, rare-disease therapies, and post-approval extensions where the EMA centralised procedure has not yet completed in the relevant indication.
The Nordic countries share several operational features: each has a small population with high specialty-care concentration in a few academic hospitals (Karolinska in Stockholm, Rigshospitalet in Copenhagen, Oslo University Hospital, Helsinki University Hospital), each has a national pharmacy agency that operates independently of the EMA centralised procedure for compassionate-use decisions, each has a national reimbursement system that may or may not cover compassionate-use medicines depending on the indication. The Swedish licensgranted, Danish udleveringstilladelse, Norwegian registreringsfritak, and Finnish erityislupa are operationally similar though legally distinct.
This page consolidates Reserve Meds's operational view of the Compassionate Use (Nordic) framework across the ten destination countries where we currently coordinate cross-border supply. Earlier in our content build we maintained separate per-country sub-pages for each Compassionate Use (Nordic)-in-country combination; those sub-pages remain available for archival reference but are no longer separately indexed, and the operational intelligence they carried has been folded into the country-compatibility table below.
Reserved for you.
Who can use Compassionate Use (Nordic)
Nordic compassionate use is used by hospital-affiliated physicians (the typical Nordic specialty-care model is hospital-based) on behalf of individual patients or small cohorts. The treating physician submits the application; the dispensing pharmacy must be authorised to receive imported unregistered medicines (typically a hospital pharmacy). Cross-border patients from outside the Nordic region cannot directly use a Nordic compassionate-use permit, but the existence of a Nordic authorisation is a useful regulatory precedent for destination-country regulators considering parallel programmes.
In practical terms, a Reserve Meds case opens when the treating physician has identified the clinical need, has reached a decision to prescribe a specific medicine, and has determined that the locally available route is unsuitable or unavailable. We then layer the regulatory and supply-chain coordination on top of that clinical decision; we do not originate the prescribing question and we do not advise on the clinical choice. The decision sits with the physician throughout.
Drug categories typically covered under Compassionate Use (Nordic)
Specialty oncology agents in late-Phase 3 development or post-EMA approval but pre-Nordic launch, rare-disease biologics, advanced therapy medicinal products (gene and cell therapies in pre-Nordic registration), paediatric extensions of adult-approved medicines, and post-approval indications not yet through EMA centralised review.
The medicine itself must be source-country approved or in active regulatory development under a recognised reference authority (typically the US FDA, the European Medicines Agency, the UK MHRA, the Japan PMDA, or Health Canada). Most destination regulators will not authorise a Compassionate Use (Nordic) import for a medicine that lacks a recognised reference authorisation anywhere in the world, because the regulator's risk assessment leans on the source-country review as a substitute for its own.
Country compatibility
The table below summarises how the Compassionate Use (Nordic) framework is recognised across the ten destination countries where Reserve Meds currently coordinates cross-border supply. The "Accepts Compassionate Use (Nordic) dossiers" column reflects whether the destination regulator typically reviews and grants permits on the strength of a Compassionate Use (Nordic) clinical justification packet, or whether the patient must use a different parallel framework on the receiving side. Timelines reflect routine cases with a complete documentation set; first-import scenarios, paediatric weight-banded presentations, advanced therapy medicinal products, and large multi-cycle quantities can extend the regulator review by several weeks.
| Country | Local pathway equivalent | Accepts Compassionate Use (Nordic) dossiers? | Typical timeline | Local regulator |
|---|---|---|---|---|
| Bahrain | NHRA Compassionate / Special Import Permit | Indirect (reference precedent only) | 5 to 15 business days | NHRA |
| Egypt | EDA Single-Patient Import (Decree 425) | Indirect (reference precedent only) | 10 to 25 business days | EDA |
| India | Rule 36 personal-use import (D&C Rules 1945) | Indirect (reference precedent only) | 7 to 21 business days | CDSCO |
| Jordan | JFDA Compassionate / Special Use Import | Indirect (reference precedent only) | 10 to 20 business days | JFDA |
| Kuwait | MoH Unregistered Medicine Import Permit | Indirect (reference precedent only) | 10 to 20 business days | KDFC (MoH) |
| Lebanon | MoPH Special Import for Named Patient | Indirect (reference precedent only) | 10 to 25 business days | MoPH |
| Oman | MoH Compassionate / Named-Patient Import | Indirect (reference precedent only) | 10 to 20 business days | MoH-DGPADC |
| Qatar | MoPH Single-Patient Unregistered Drug Import | Indirect (reference precedent only) | 10 to 20 business days | MoPH-DPA |
| Saudi Arabia | SFDA Personal Importation Permit | Indirect (reference precedent only) | 10 to 25 business days | SFDA |
| United Arab Emirates | EDE Unregistered Medicine Import Permit | Indirect (reference precedent only) | 5 to 15 business days | EDE |
Notes. "Indirect" means the destination regulator does not directly accept Compassionate Use (Nordic) authorisation as the legal basis for import but does recognise a Compassionate Use (Nordic) authorisation as supporting precedent within its own named-patient or compassionate-use review. "Not applicable" means the framework is not a patient-access pathway in the cross-border sense and is shown here for completeness. Regulator names: NHRA (Bahrain), EDA (Egypt), CDSCO (India), JFDA (Jordan), KDFC (Kuwait), MoPH (Lebanon), MoH-DGPADC (Oman), MoPH-DPA (Qatar), SFDA (Saudi Arabia), and EDE (United Arab Emirates, federal from 29 December 2025).
Documentation required
A Compassionate Use (Nordic) application is typically assembled in coordination with the treating physician, the dispensing facility, and the cross-border supply partner. The documentation set below covers the routine case; specific destination countries may require additional items (most frequently a hospital ethics committee notification for paediatric or complex cases, and an insurer pre-authorisation letter where the patient intends to seek reimbursement).
- Treating physician's clinical justification documenting the patient's condition and absence of satisfactory authorised alternatives.
- Patient clinical history.
- Informed consent specific to compassionate use.
- Hospital pharmacy authorisation to receive imported unregistered medicines.
- Manufacturer letter confirming supply.
- Periodic reporting for cohort cases.
- Patient identifier as required by the national regulator.
Typical timeline
Nordic regulators are among the fastest in Europe: routine cases typically complete in 5 to 15 business days from a complete submission. Complex cases (advanced therapy medicinal products, first-import scenarios, paediatric weight-banded presentations) can extend to 4 to 6 weeks. Cross-border patients using a parallel home-country framework typically complete in 4 to 8 weeks end-to-end.
Costs and reimbursement
Nordic reimbursement systems may cover compassionate-use medicines depending on indication and national policy; this is decided case by case by the relevant regional health authority. Cross-border patients pay the relevant per-country acquisition cost plus logistics, customs, dispensing, and coordinator fees.
Where Reserve Meds fits in
Reserve Meds is a US-based concierge coordinator for cross-border specialty medicine access. For Compassionate Use (Nordic) cases, we coordinate the US-side sourcing through a DSCSA-compliant specialty channel, prepare the documentation packet your physician submits, coordinate validated cold-chain logistics with continuous temperature logging into the destination country, and assign a single named coordinator through the case. We do not replace your treating physician, we do not replace the destination-country regulator, and we do not replace your dispensing pharmacy. We coordinate the supply side so the physician can focus on patient care.
For each of the ten destination countries above, we publish a country-specific page documenting the operational realities (which dispensing facilities handle named-patient cases, how the cold chain is verified at the local airport, how the dispensing pharmacy releases the medicine, and what the typical insurer interaction looks like). Those country pages, combined with this pathway page and the specific drug pages, give the prescribing physician and the patient a coherent picture of what to expect before any commitment is made.
Our concierge fee is itemised separately on every firm quote alongside the drug acquisition cost, international logistics, customs, and dispensing pharmacy handling. The patient sees the full breakdown before deciding to proceed; we do not bundle costs and we do not charge an intake deposit. If the case cannot proceed for regulatory or supply reasons, we say so before any payment is taken.
Next step
If your treating physician has identified a clinical need that fits the Compassionate Use (Nordic) framework and you are weighing the cross-border route, the next step is a short intake. We confirm eligibility within 24 to 48 hours and send a documentation kit to your physician.
Reserved for you.